Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Brain Neoplasms 1

Interventions

Dacarbazine 25Nivolumab 24pembrolizumab 19Ipilimumab 18Interferon-alpha 10trametinib 8Vemurafenib 8dabrafenib 7aldesleukin 7Temozolomide 7Introns 7Interferon alpha-2 6Interleukin-2 5Cisplatin 5Chemotherapy, Adjuvant 5talimogene laherparepvec 4cemiplimab 4binimetinib 4Radiotherapy 4Paclitaxel 4Granulocyte-Macrophage Colony-Stimulating Factor 4sargramostim 3encorafenib 3cobimetinib 3Vinblastine 3Surgical Procedures, Operative 3Specimen Handling 3Sodium Chloride 3Radiosurgery 3Opdualag 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Melanoma × HBI-8000 × Clear all
NCT04674683 2025-09-24

Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

HUYABIO International, LLC.

Phase 3 Active not recruiting
450 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡